Application of sequencing, liquid biopsies and patient-derived xenografts for personalized medicine in melanoma

Girotti, María Romina; Gremel, Gabriela; Lee, Rebecca; Galvani, Elena; Rothwell, Dominic G.; Mandal, Amit Kumar; Lim, Kok Haw Jonathan; Saturno, Grazia; Furney, Simon J.; Baenke, Franziska; Pedersen, Magnus; Smith, M. T.; Fusi, Alberto; Dhomen, Nathalie; Brady, Gerard; Lorigan, Paul; Marais, Richard

doi:10.1016/s0959-8049(16)61681-7

Cited by 39 publications

(58 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By transplanting the patient's tumor masses into mice, heterogeneous PDX models can maintain a variety of features of the patient's tumor such as histology, genomic signature, and cellular heterogeneity (Park et al, ). Girotti et al () constructed PDX models retaining the histological features of a patient's tumor that were used to determine a preferred treatment were performed on the patient. Whittle, Lewis, Lindeman, and Visvader () also pointed out that PDX models generated from fresh tumor specimens recapitulate the diversity of breast cancer and reflect the histopathology, tumor behavior, and the metastatic properties of the original tumor.…”

Section: Applications Of Heterogeneous Tumor Modelsmentioning

confidence: 99%

Review on biofabrication and applications of heterogeneous tumor models

Liu

Yao

Pang

et al. 2019

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Resolving the origin and development of tumor heterogeneity has proven to be a crucial challenge in cancer research. In vitro tumor models have been widely used for both scientific and clinical research. Currently, tumor models based on 2D cell culture, animal models, and 3D cell‐laden constructs are widely used. Heterogeneous tumor models, which consist of more than one cell type and mimic cell–cell as well as cell–matrix interactions, are attracting increasing attention. Heterogeneous tumor models can serve as pathological models to study the microenvironment and tumor development such as tumorigenesis, invasiveness, and malignancy. They also provide disease models for drug screening and personalized therapy. In this review, the current techniques, models, and oncological applications regarding 3D heterogeneous tumor models are summarized and discussed.

show abstract

Section: Applications Of Heterogeneous Tumor Modelsmentioning

confidence: 99%

Review on biofabrication and applications of heterogeneous tumor models

Liu

Yao

Pang

et al. 2019

J Tissue Eng Regen Med

View full text Add to dashboard Cite

show abstract

“…The detection of increased amounts of CTCs/ctDNA may precede the radiological detection of disease progression . Moreover, such detection may aid in monitoring the response or development of resistance to targeted therapies .…”

Section: Limitations Of Liquid Biopsy In Routine Diagnosticsmentioning

confidence: 99%

Liquid biopsy to monitor melanoma patients

Gaiser

Bubnoff

Gebhardt

et al. 2018

J Deutsche Derma Gesell

View full text Add to dashboard Cite

During the last six years, several innovative, systemic therapies for the treatment of metastatic malignant melanoma (MM) have emerged. Conventional chemotherapy has been superseded by novel first-line therapies, including systemic immunotherapies (anti-CTLA4 and anti-PD1; authorization of anti-PDL1 is anticipated) and therapies targeting specific mutations (BRAF, NRAS, and c-KIT). Thus, treating physicians are confronted with new challenges, such as stratifying patients for appropriate treatments and monitoring long-term responders for progression. Consequently, reliable methods for monitoring disease progression or treatment resistance are necessary. Localized and advanced cancers may generate circulating tumor cells and circulating tumor DNA (ctDNA) that can be detected and quantified from peripheral blood samples (liquid biopsy). For melanoma patients, liquid biopsy results may be useful as novel predictive biomarkers to guide therapeutic decisions, particularly in the context of mutation-based targeted therapies. The challenges of using liquid biopsy include strict criteria for the phenotypic nature of circulating MM cells or their fragments and the instability of ctDNA in blood. The limitations of liquid biopsy in routine diagnostic testing are discussed in this review.

show abstract

“…Der Anstieg von CTCs oder ctDNA kann der radiologischen Erkennung einer Krankheitsprogression vorausgehen . Des Weiteren können Schwankungen der CTC/ctDNA‐Menge Hinweise auf ein Therapie‐Ansprechen oder die Entwicklung einer Resistenz gegenüber einer zielgerichteten Therapie geben .…”

Section: Einschränkungen Beim Einsatz Der Liquid Biopsy In Der Routinunclassified

Liquid Biopsy zur Überwachung von Melanompatienten

Gaiser

Bubnoff

Gebhardt

et al. 2018

J Deutsche Derma Gesell

View full text Add to dashboard Cite

In den letzten sechs Jahren wurden verschiedene innovative systemische Therapien zur Behandlung des metastasierten malignen Melanoms (MM) entwickelt. Die konventionelle Chemotherapie wurde durch neuartige Primärtherapien abgelöst, darunter systemische Immuntherapien (Anti-CTLA4- und Anti-PD1-Antikörper; Zulassung von Anti-PDL1-Antikörpern erwartet) und Therapien, die gegen bestimmte Mutationen gerichtet sind (BRAF, NRAS und c-KIT). Daher stehen die behandelnden Ärzte neuen Herausforderungen gegenüber, beispielsweise der Stratifizierung von Patienten für geeignete Behandlungen und der Überwachung von Langzeit-Respondern auf Progression. Folglich werden zuverlässige Methoden zur Überwachung von Krankheitsprogression oder Behandlungsresistenz benötigt. Lokalisierte und fortgeschrittene Krebserkrankungen können zur Bildung zirkulierender Tumorzellen und Tumor-DNA (ctDNA) führen, die sich in Proben von peripherem Blut nachweisen und quantifizieren lassen (Liquid Biopsy). Im Fall von Melanompatienten können die Ergebnisse von Liquid Biopsy als neuartige prädiktive Biomarker bei therapeutischen Entscheidungen hilfreich sein, insbesondere im Zusammenhang mit mutationsbasierten zielgerichteten Therapien. Die Herausforderungen bei der Anwendung der Liquid Biopsy beinhalten strikte Kriterien für den Phänotyp der zirkulierenden MM-Zellen oder ihrer Fragmente und die Instabilität von ctDNA im Blut. In diesem Übersichtsartikel diskutieren wir die Beschränkungen der Liquid Biopsy hinsichtlich ihrer Anwendung in der Routinediagnostik.

show abstract

Application of sequencing, liquid biopsies and patient-derived xenografts for personalized medicine in melanoma

Cited by 39 publications

References 0 publications

Review on biofabrication and applications of heterogeneous tumor models

Review on biofabrication and applications of heterogeneous tumor models

Liquid biopsy to monitor melanoma patients

Liquid Biopsy zur Überwachung von Melanompatienten

Contact Info

Product

Resources

About